Targeting An Rnaseh2 Defect In Chronic Lymphocytic Leukaemia With Parp Inhibitors
BLOOD(2018)
Abstract
The therapeutic exploitation of molecular defects within the DNA damage response (DDR) in tumour cells has become an important treatment paradigm. ‘Synthetic lethality’ relies on pharmacological inhibition of pathways upon which DDR-deficient tumour cells have become dependent for their survival. This induces an intolerable level of unrepaired DNA damage in the tumour cells resulting in cell death, whilst sparing DDR-proficient normal cells
MoreTranslated text
Key words
rnaseh2 defect,parp inhibitors,chronic lymphocytic leukaemia
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined